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This study describes vancomycin prescribing patterns in an average complexity hospital and compare the guidelines
proposed by the Hospital Infection Control Practices Advisory Committee (HICPAC). The study was conducted in a
256-bed secondary-care hospital. Data were collected of all patients given vancomycin from March 2003 to February
2004, using a standardized chart-extraction form designed. Appropriate and inappropriate use was reviewed according
to the Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines on prudent vancomycin use.
Out of 118 prescriptions, 95 (80.5%) were considered appropriate. Out of these 95 orders, 77 (81.1%) were administered
for empiric treatment of suspected Gram-positive infections, 17 (17.9%) were administered for treatment of proven
Gram-positive infections (76.5% identified as Staphyloccocus aureus-like agents) and 1 (1.0%) for beta-lactam
allergy. The majority of the patients (96.6%) had recently used an antimicrobial medication (3 months). The mean
pre-treatment hospitalization period was 11±10 days. Out of the 118 treatments, 67 (56.8%) were for nosocomial
infections. The more frequent indications for vancomycin use were pneumonia (48.3%) and primary sepsis (18.6%),
accounting for more than 66% of all treatments. No restriction policy was suggested because vancomycin use was
considered adequate in the majority of the treatment cases. The broad empiric use of this antimicrobial was greater
than expected in the institution and its use should be revised.
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The development of resistance to multiple drugs in Gram-
positive pathogens is a serious clinical problem. Inadequate
empiric therapy enhances the potential risk of developing
resistance by 50% to 60% [1,2].
The increasing incidence of vancomycin enterococci (VRE)
and the potential transfer of genetic factors responsible for
vancomycin resistance to different Gram-positive
microorganisms, including Staphylococcus aureus [3-7] is an
international concern. Infections caused by strains of
Staphylococcus aureus with reduced susceptibility to
vancomycin (minimum inhibitory concentration = 8 μg/mL)
have been described. In Japan and in the United States. All
cases occurred following a prolonged course of vancomycin
therapy [8-10]. In the United States cases of vancomycin
resistant Staphylococcus aureus (VRSA) clinical infections
were reported, in 2002 [7,11-13]. S. aureus intermediately
resistant to Vancomycin has been described in Brazil [14-16].
Enterococcus sp. is the second most commonly isolated
nosocomial pathogen. It is responsible for 8% of hospital
acquired bloodstream infections [17,18]. The prevalence of
vancomycin-resistant enterococcus (VRE) infections
increased 20-fold over the past 10 years [19,20], especially in
high-risk patient populations. Between 1989 and 1993, the
proportion of enterococcal isolates resistant to vancomycin
among in-patients increased from 0.3% to 7.9% and from 0.4%
to 13.6% in intensive-care unit patients [21].
Over the last decade, vancomycin-resistant enterococci
(VRE) have become a common cause of nosocomial infections
in Western Europe and in the United States [4,20,22-26]. The
occurrence of VRE in National Nosocomial Infections
Surveillance (NNIS) hospitals has been associated with larger
size hospitals (i.e., a hospital with at least 200 beds) and
university affiliation [5,27]. The NNIS reported a vancomycin
resistance rate of 26.3% for enterococci isolated from patients
with nosocomial infections in intensive care units (ICUs) in
2000 [28,29]. In Brazil, the first case was reported in São Paulo
[30]. Other cases occurred in different hospitals and, by 1998,
VRE had spread throughout the country [31]. Disease severity
controlled studies found that vancomycin resistance was
predictive of increased mortality [32-34]. Comparing patients
with vancomycin-susceptible isolates, patients with VRE
bacteremia exhibit significantly increased mortality rates (17.2%
vs. 36.0%) [18, 21].
In 1995, the Centers for Disease Control and Prevention
(CDC) and the Hospital Infection Control Practices Advisory
Committee (HICPAC) issued guidelines to prevent the spread
of vancomycin resistance [5]. Several studies demonstrated
the benefit of stool scrutiny in decreasing the rate of VRE
infections in healthcare facilities [4,22-25,32]. The objective
of this study was to evaluate intravenous vancomycin use at
a secondary-care teaching hospital and to estimate the
proportion of intravenous vancomycin prescribed for an
indication meeting the HICPAC guidelines, using actual
information available in chart-review.
Material and Methods
The University Hospital provides services to the
university community and local population and has a 10-bed
intensive care unit and a 10-bed semi intensive care unit. It is
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a secondary-care teaching hospital, with 256 beds. The
Pharmacy Service is centralized and attends hospitalized
patients on an individual basis. Prescriptions are reviewed in
each clinic by the pharmacist in charge. Drugs are dispensed
to patients, for a maximum period of 24 hours (doses for oral
or enteral administration are dispensed ready for use and doses
for potential administration are dispensed without
manipulation, with the identification of product and patient,
dilution calculation and administration precautions).
Study Population
The Study Population included Patients who received
intravenous vancomycin between March 2003 and February
2004, as in-patients of a 256-bed, secondary-care teaching
hospital. This hospital provides services to the university
community and local population and has a 10-bed intensive
care unit and a 10-bed semi intensive care unit.
Data Collection and Analysis
All new vancomycin prescriptions were evaluated. The
order form identified new cases. A standard design chart-
extraction form was used for entering the data. These data
included underlying diagnosis, history of drug allergy,
demographic characteristics, hospital location, indications for
vancomycin use, including culture and sensitivity data,
antimicrobial treatment in the preceding three months, nature
of infection, suspension of treatment when necessary or
possible and antimicrobial replacement, renal insufficiency
and dosing regimen.
Appropriate Use Criteria
Use was considered appropriate if the clinical indication
met the HICPAC criteria. In cases of empiric use in patients
with risk factors due to hospital epidemiology – high
prevalence of methicillin-resistant Staphylococcus aureus
(MRSA). Accordingly, the Hospital Infection Control
Commission identified during the study period nine nosocomial
infections caused by Staphylococcus aureus. Out of these,
eight were MRSA.
Inappropriate Use was Subdivided
a. Use of empiric therapy without the presence of risk
factors;
b. Continued empiric use for presumed infections in patients
whose cultures were negative for beta-lactam-resistant
Gram-positive microorganisms;
c. Treatment of infections caused by beta-lactam-sensitive
Gram-positive microorganisms, without allergy history to
beta-lactam antimicrobials;
d. Treatment in response to a single positive blood culture
for coagulase-negative staphylococcus, if other blood
cultures taken during the same time-frame are negative;
e. Systemic or local prophylaxis for infection or
colonization of indwelling central or peripheral
intravascular catheters.
Secondary Conformity Analysis Classification of
Inappropriate Use
Vancomycin use was studied after the culture results
became available. If cultures revealed methicillin-sensitive
staphylococci, or another relevant pathogen, maintenance of
vancomycin use was considered inappropriate.
Renal Function Monitoring and Dosing Regimen Correction
Renal function monitoring was reviewed (serum urea or
creatinine). When these tests were performed at least twice a
week, monitoring was considered adequate. The dosing
regimen, including adjustment for renal insufficiency, was
evaluated using the normogram [35].
Results
Vancomycin was prescribed 118 times during the year
audited (March 2003 to February 2004). The average age was
49±29 years. The mean pre-treatment hospitalization period was
11±10 days. The most frequent indications for vancomycin use
were pneumonia (48.3%), septicemia (18.6%), peritonitis (7.6%),
catheter local infection (5.1%), surgical wound infection (4.2%),
and meningitis (2.5%). The medical specialties that prescribed
the drug most were: intensive care unit (37.3%), semi-intensive
care unit (16.9%), medical clinic (13.6%), surgical clinic (11.0%)
and pediatric intensive care unit (10.2%).
Out of the 118 treatments, 67 (56.8%) were nosocomial
infections, 11 (9.3%) were healthcare-related infections and
40 (33.9%) community infections. The majority of the patients
(96.6%) had used antimicrobials recently (3 months).
Vancomycin use was considered consistent with the
HICPAC guidelines in 95 (80.5%) patients. Out of these, 77
(81.1%) for empiric treatment of suspected Gram-positive
infections, 17 (17.9%) for treatment of proven Gram-positive
infections (76.5% identified Staphyloccocus aureus-like
agents) and 1 (1.0%) for beta-lactam allergy (Table 1).
Out of the 95 treatments considered appropriate, 5 (5.3%)
had cultures that justified the antimicrobial discontinuation
but only 3 (3.2%) actually had the antimicrobial suspended.
Among the 23 (19.5%) treatments considered inappropriate,
15 (65.2%) were community infections and 8 (34.8%) were
treatments for agents that did not warrant that treatment.
Table 1. Results of vancomycin audit.
Use N (%)
Appropriate 95 (80.5%)
Empiric therapy with risk factors 77 (81.1%)
Treatment of proven Gram-positive 17 (17.9%)
infections
Beta-lactam allergy 1 (1.0%)
Inappropriate 23 (19.5%)
Empiric therapy without risk factors; 15 (65.2%)
Continued empiric use without further 8 (34.8%)
evidence of Gram-positive infection
Vancomycin Use in an University Hospital
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Among the 23 cases of inappropriate treatment, 7 (26.1%)
began in a medical clinic, 6 (26.1%) in intensive care units, 4
(17.4%) in pediatric intensive care units, 3 (13.0%) in a surgical
clinic, 2 (8.7%) in semi-intensive care units and 1 (4.3%) in a
nursery.
The average treatment duration was 12±10 days. The major
dosing regimen employed was 1 gram every 12 hours and 500
milligrams every 6 hours, in 52 (44.1%) and 7 (5.9%) treatments,
respectively. The other dosing regimens were specifically
adjusted for renal insufficiency. Five patients, 60 years old or
over, used a dosing regimen of 1 gram every 24 hours, despite
the absence of renal insufficiency. This is justified by the
slow metabolism [35]. Out of 23 children, 2 (8.7%) received a
dose of the antimicrobial that was greater than necessary.
When the report on renal insufficiency was assessed,
before or during the treatment with the antimicrobial, forty-
four patients (37.3%) reported suffering from insufficiency
before the treatment and 17 (14.4%) after its use. The function
was monitored in 123 (93.4%) patients and the dose wasn’t
corrected for 2 (5.9%) patients who presented renal
insufficiency (Table 2). Among the patients not monitored, 5
(35.7%) were children.
adequate, because of hospital epidemiology (Table 1). In a
Brazilian tertiary hospital, the empiric treatment was
responsible for 81.1% of appropriate vancomycin use (because
of hospital epidemiology) and 65.2% was inappropriate [36].
In other studies, the empiric treatment with vancomycin was
considered the second largest category of inappropriate use
(26%), and in others two studies it was considered the first,
with 67% of inappropriate use [8,27,37].
For instance, the HICPAC guidelines state that vancomycin
is an appropriate treatment for infections caused by Gram-
positive microorganisms in patients with serious allergies to
beta-lactam antibiotics; we considered as “appropriate”, the
only case of allergy that was reported in a patient’s chart
although the severity of the allergy was not specified.
According to Morgan et al. (1997), the average treatment
duration was 4.7 days, influenced by the prophylactic use [27].
The prophylactic use is very common in the United Sates, but
less frequent in Brazil. Failure to discontinue the documented
inadequate treatments indicates that greater attention to a review
of the medical conduct is required. No correction of dosing
regimen occurs when there is renal insufficiency concern, mainly
because the hospital attends an older population.
Surveillance of the posological scheme was inappropriate.
Vancomycin misuse may be associated with clinical failure,
toxicity or super-infections, such as Gram-negative bacteremia
in children [41]. The higher dose regimen in children
demonstrates failures in this antimicrobial prescription and
dispensation system, considering an ordinarily corrected order
by the clinic pharmacist. Vancomycin use was strongly
associated with Gram-negative bacteremia in children [41].
An explanation was that severe infectious diseases,
predominantly caused by Gram-negative bacteria, induce the
use of central venous catheters, which in turn induces the
use of vancomycin. However, the association between
vancomycin and Gram-negative bacteremia is still regarded
as strong when the study was restricted to children without
central venous catheter [41].
Studies suggest that, even in the absence of restriction
policies, vancomycin use is not more than 40% of the guidelines
recommendations [36,38,39,42]. Other studies have shown that
antibiotic control measures can reduce total vancomycin use
[18,39]. Additionally, the implementation of pharmacy policies
designed to reduce the number of initial orders of vancomycin
were associated with a reduction of the inappropriate use of
this antimicrobial and rate of VRE infections in healthcare
facilities [1,8,20,22-25,35]. Hospital pharmacies represent an even
more important control point for this drug [4].
In the institution analyzed, vancomycin use was considered
cautious. We believe that other antimicrobials require more
attention and no restriction policy was suggested. But, due to
the large empiric use of these antimicrobials there is a consensus
that vancomycin use should be monitored.
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Table 2. Adjustment of posology, according to renal function.
Adjustment N (%)
Not required 57 (48.3%)
Required 61 (51.7%)
Correctly adjusted 57 (93.4%)
Incorrectly adjusted 2 (3.3%)
No correction performed 2 (3.3%)
Discussion
In March 2003 another study on the use of vancomycin in
a Brazilian tertiary hospital was initiated by one of the authors
of this paper. It is of notice that in both hospitals, MRSA
prevalence is high, which justifies the empiric use of
vancomycin in the treatment of hospital infections. MRSA
prevalence in HU is 41% and 92 (78%) patients received empiric
treatment for suspected Gram-positive infections, which is
consistent with the results of the study in the other Brazilian
hospital (78% of the empiric treatment with vancomycin) [36].
The empiric use in other studies [8,27,37] varied between
33% and 71%, among all patients that received vancomycin,
Success rates in the management of Gram-positive infections
(post surgical patients, ventilator-associated pneumonia,
peritonitis, bacteremia and meningitis) were enhanced by early
therapy with active agents against the organisms later
identified by the appropriate culture. Inadequate therapy is
closely correlated with adverse patient outcomes, including
increased rates of hospital mortality [35,38,39].
Only one study confirmed an MRSA proportion considered
high, more than 20% MRSA [40]. The empiric use was
responsible for 81.1% of the prescriptions considered
Vancomycin Use in an University Hospital
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